Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor

Conclusion: AMG416 was well tolerated and appears to be an effective agent for the treatment of SHPT in patients on hemodialysis.Am J Nephrol 2015;42:379-388
Source: American Journal of Nephrology - Category: Neurology Source Type: research